untreated;
Showing 26 - 50 of 7,098
Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Rituximab, Copanlisib)
Recruiting
- Follicular Lymphoma
- +2 more
- Rituximab
- Copanlisib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
LOng-Term Fate of Moderate Aortic Regurgitation Left Untreated
Completed
- Aortic Regurgitation
- Mitral Regurgitation
- Mitral valve surgery
- Aortic valve surgery
-
Milan, ItalyIRCCS Ospedale San Raffaele
Mar 16, 2023
Carcinoma, Hepatocellular Trial (Atezolizumab, Bevacizumab, Tiragolumab)
Not yet recruiting
- Carcinoma, Hepatocellular
- Atezolizumab
- +3 more
- (no location specified)
Jun 14, 2023
Untreated Mantle Cell Lymphoma Trial in Suzhou (zanubrutinib and rituximab, BEAM pretreatment, zanubrutinib maintenance)
Recruiting
- Untreated Mantle Cell Lymphoma
- zanubrutinib and rituximab
- +2 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Aug 16, 2022
Previously Untreated Peripheral T-cell Lymphoma Trial in Tampa, Saint Louis, New York (CC-486 Administration, CHOP
Active, not recruiting
- Previously Untreated Peripheral T-cell Lymphoma
- CC-486 Administration
- CHOP Administration
-
Tampa, Florida
- +3 more
Jan 18, 2023
Cervical Intraepithelial Neoplasia Grade 2, DNA Methylation Trial in Maribor (Testing DNA methylation test for predicting
Recruiting
- Cervical Intraepithelial Neoplasia Grade 2
- DNA Methylation
- Testing DNA methylation test for predicting prognosis of untreated CIN 2
-
Maribor, SloveniaUniversity Medical Centre Maribor
Nov 14, 2022
Bacterial Vaginosis Trial in Sweden (pHyph)
Not yet recruiting
- Bacterial Vaginosis
- pHyph
-
Linköping, Sweden
- +3 more
Nov 7, 2023
Urothelial Carcinoma Trial (disitamab vedotin, pembrolizumab, gemcitabine)
Not yet recruiting
- Urothelial Carcinoma
- disitamab vedotin
- +4 more
- (no location specified)
Jun 9, 2023
Large B-Cell Lymphoma Trial in Xi'an (Glofitamab, Polatuzumab vedotin, Rituximab)
Not yet recruiting
- Large B-Cell Lymphoma
- Glofitamab
- +5 more
-
Xi'an, ChinaFirst Affiliated Hospital of Medical College of Xi'an Jiaotong U
Sep 14, 2023
Tumors, Rectal Trial (Dostarlimab)
Not yet recruiting
- Neoplasms, Rectal
- Dostarlimab
- (no location specified)
Feb 2, 2023
Untreated Myelodysplastic Syndrome Trial in France (Onureg + Venetoclax)
Not yet recruiting
- Untreated Myelodysplastic Syndrome
- Onureg + Venetoclax
-
Angers, France
- +9 more
Mar 13, 2023
Fate at Long-term of Mild to Moderate Bicuspid Aortic Valve
Completed
- Bicuspid Aortic Valve
- Ascending Aorta Aneurysm
- Ascending aorta replacement
-
Milan, ItalyIRCCS Ospedale San Raffaele
Apr 28, 2023
Schizophrenia, First Episode Psychosis Trial in Glen Oaks, Queens (search engine advertisement campaign)
Active, not recruiting
- Schizophrenia
- First Episode Psychosis
- search engine advertisement campaign
-
Glen Oaks, New York
- +1 more
Sep 27, 2022
Non Small Cell Lung Cancer, Brain Metastases Trial (Cadonilimab)
Not yet recruiting
- Non Small Cell Lung Cancer
- Brain Metastases
- (no location specified)
Apr 2, 2023
Urothelial Cancer Trial in Beijing (Atezolizumab, RO7247669, Tiragolumab)
Recruiting
- Urothelial Cancer
- Atezolizumab
- +2 more
-
Beijing, ChinaBeijing Cancer Hospital
Jan 18, 2023
Pseudotumor Cerebri, Idiopathic Intracranial Hypertension (IIH) Trial in Phoenix, Seattle (Dural Venous Sinus Stenting,
Recruiting
- Pseudotumor Cerebri
- Idiopathic Intracranial Hypertension (IIH)
- Dural Venous Sinus Stenting
- Cerebrospinal Fluid Shunting
-
Phoenix, Arizona
- +1 more
Jan 17, 2023
Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)
Completed
- Waldenstrom's Macroglobulinemia
-
Boston, Massachusetts
- +1 more
Dec 5, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 19, 2022
Metastatic Melanoma, Unresectable Melanoma, Melanoma Trial (Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover
Not yet recruiting
- Metastatic Melanoma
- +2 more
- Lifileucel plus Pembrolizumab
- Pembrolizumab with Optional Crossover Period
- (no location specified)
Feb 13, 2023
Lymphoma, Follicular, Follicular Lymphoma Trial in Saint Louis (Mosunetuzumab, Polatuzumab vedotin)
Recruiting
- Lymphoma, Follicular
- Follicular Lymphoma
- Mosunetuzumab
- Polatuzumab vedotin
-
Saint Louis, MissouriWashington University School of Medicine
Nov 14, 2022